What the Study Measured Researchers evaluated orforglipron in adults with obesity and in people living with type 2 diabetes
From Diabetes to MASH: Evolution of GLP-1 Agonist Applications GLP-1 agonists have demonstrated significant benefits in weight management, primarily through appetite suppression and enhanced satiety5
Report any suspected side effects to the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk
Side Effect Profiles: All Tirzepatide Forms (Same Side Effects): Nausea: 30-37% Diarrhea: 19-23% Vomiting: 9-17% Constipation: 10-17% Abdominal pain: 8-11% All Semaglutide Forms (Same Side Effects): Nausea: 44% Diarrhea: 30% Vomiting: 24% Constipation: 24% Abdominal pain: 20% Side effects are determined by the medication molecule, not the manufacturer
The appetite-suppressing effect of semaglutide GLP-1 if is gradual
The Rybelsus Vision Loss Lawsuit is an active lawsuit See If You Qualify Rybelsus, an oral semaglutide prescribed to treat type 2 diabetes but commonly used for weight loss, has been linked to severe vision side effects, including blurry vision, vision loss, and blindness